F. Paul

发表

Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders

H. Hartung, R. Gold, S. Meuth, 2021, Neurology® Neuroimmunology & Neuroinflammation.

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning

Fabian J Theis, C. Gieger, M. Waldenberger, 2018 .

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning

Tim Kacprowski, Till F M Andlauer, Fabian J Theis, 2020, PLoS Comput. Biol..

Aquaporin 4 antibody positive central nervous system autoimmunity and multiple sclerosis are characterized by a distinct profile of antibodies to herpes viruses

S. Cepok, B. Hemmer, H. Tumani, 2010, Neurochemistry International.

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Till F. M. Andlauer, M. Mühlau, H. Hartung, 2020, Proceedings of the National Academy of Sciences.

Alterations of NK Cell Phenotype During Pregnancy in Multiple Sclerosis

P. Arck, J. Bellmann-Strobl, C. Heesen, 2022, Frontiers in Immunology.

CTGF/CCN2 has a possible detrimental role in the inflammation and the remyelination failure in the early stages of multiple sclerosis

L. Fuchs, A. Karni, H. Kolb, 2022, Journal of Neuroimmunology.

Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry

U. Zettl, C. Kleinschnitz, C. Warnke, 2022, Neurology and Therapy.

Association of obesity with disease outcome in multiple sclerosis

J. Lünemann, F. Zipp, B. Hemmer, 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

Diagnosis and classification of optic neuritis

G. Plant, L. Leocani, P. Calabresi, 2022, The Lancet Neurology.

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Jeffrey A. Cohen, Islam M. Zaydan, Gregory F. Wu, 2022, The Lancet Neurology.

Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial

H. Hartung, K. Fujihara, B. Weinshenker, 2022, EBioMedicine.

Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate

F. Paul, K. Ruprecht, S. Jarius, 2014, Journal of Neuroinflammation.

Effects of the COVID-19 Pandemic on Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Diseases

J. Bellmann-Strobl, T. Etgen, F. Then Bergh, 2023, Neurology: Neuroimmunology & Neuroinflammation.

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

F. Paul, H. Hartung, U. Ziemann, 2012, Journal of Neuroinflammation.

In vivo stiffness of multiple sclerosis lesions is similar to that of normal-appearing white matter.

I. Sack, J. Braun, S. Hetzer, 2021, Acta biomaterialia.

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

F. Paul, T. Ziemssen, H. Tumani, 2017, Journal of Neuroinflammation.

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture ofmajor depressive disorder

Li, Katharina, Warren W. Kretzschmar, 2018 .

Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis

F. Paul, O. Werz, F. Leypoldt, 2020, Scientific Reports.

Myelin-oligodendrocyte glycoprotein antibody-associated disease

O. Ciccarelli, Jacqueline Palace, A. Traboulsee, 2021, The Lancet Neurology.

Subcortical Volumes as Early Predictors of Fatigue in Multiple Sclerosis

H. Hartung, V. Fleischer, F. Zipp, 2021, Annals of neurology.

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD

Jacqueline Palace, K. Fujihara, D. Rotstein, 2023, Neurology: Neuroimmunology & Neuroinflammation.

A Response to: Letter to the Editor Regarding “Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder”

K. Fujihara, D. Wingerchuk, S. Pittock, 2022, Neurology and Therapy.

A blood based 12-miRNA signature of Alzheimer disease patients

Sabine C. Mueller, Karen S. Frese, T. Bártfai, 2013, Genome Biology.

Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (S5.003)

C. Pozzilli, Jacqueline Palace, H. Kim, 2023, Sunday, April 23.

Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature

M. Salvetti, K. Ruprecht, C. Münch, 2012, Multiple sclerosis.

Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002)

C. Pozzilli, Jacqueline Palace, H. Kim, 2023, Sunday, April 23.

risk variants and refine the genetic architecture ofmajor depressive disorder

Li, Katharina, Warren W. Kretzschmar, 2022 .

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset

Jacqueline Palace, J. Palace, R. Karabudak, 2014, Multiple sclerosis.